GRAL supply chain intelligence for GRAIL, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| MADISON-INDUSTRIES | MADISON-INDUSTRIES | 92% | Madison Industries...who is our sole supplier of tubes used for sample collection |
| TWIST-BIOSCIENCES-CORPORATION | TWIST-BIOSCIENCES-CORPORATION | 92% | Twist Biosciences Corporation...who is the sole supplier of our DNA probes |
| SINGLE-VENDORS | SINGLE-VENDORS | 80% | The Company sources certain laboratory equipment, supplies and reagents used to perform testing services and research and development from single vendors. |
| TWST | Twist Bioscience Corporation | 72% | difficult for us to offset the costs of our royalties, including the high single-digit royalty that we will be required to pay to Illumina in perpetuity or our royalties payable to the Chinese Univer… |
| TWST | Twist Bioscience Corporation | 72% | Reciprocal relationship from TWST graph: Reciprocal relationship from GRAL graph: Reciprocal relationship from TWST graph: Reciprocal relationship from GRAL graph: difficult for us to offset the cost… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BIOPHARMACEUTICAL-COMPANIES | BIOPHARMACEUTICAL-COMPANIES | 90% | Accounts receivable primarily arise from testing services performed in the U.S. and are primarily with biopharmaceutical companies, healthcare organizations, employers, digital health platforms, conc… |
| CONCIERGE-MEDICINE-PRACTICES | CONCIERGE-MEDICINE-PRACTICES | 90% | Accounts receivable primarily arise from testing services performed in the U.S. and are primarily with biopharmaceutical companies, healthcare organizations, employers, digital health platforms, conc… |
| DIGITAL-HEALTH-PLATFORMS | DIGITAL-HEALTH-PLATFORMS | 90% | Accounts receivable primarily arise from testing services performed in the U.S. and are primarily with biopharmaceutical companies, healthcare organizations, employers, digital health platforms, conc… |
| EMPLOYERS | EMPLOYERS | 90% | Accounts receivable primarily arise from testing services performed in the U.S. and are primarily with biopharmaceutical companies, healthcare organizations, employers, digital health platforms, conc… |
| HEALTHCARE-ORGANIZATIONS | HEALTHCARE-ORGANIZATIONS | 90% | Accounts receivable primarily arise from testing services performed in the U.S. and are primarily with biopharmaceutical companies, healthcare organizations, employers, digital health platforms, conc… |
| INDIVIDUALS | INDIVIDUALS | 90% | Accounts receivable primarily arise from testing services performed in the U.S. and are primarily with biopharmaceutical companies, healthcare organizations, employers, digital health platforms, conc… |
| ABBOTT-LABORATORIES | ABBOTT-LABORATORIES | 85% | Exact Sciences Corporation (recently announced to be acquired by Abbott Laboratories) |
| ABT | Abbott Laboratories | 85% | Reciprocal relationship from ABT graph: Reciprocal relationship from GRAL graph: Exact Sciences Corporation (recently announced to be acquired by Abbott Laboratories) |
| EXACT-SCIENCES-CORPORATION | EXACT-SCIENCES-CORPORATION | 85% | There are market participants in the cancer detection space both in the United States and abroad, including Exact Sciences Corporation (recently announced to be acquired by Abbott Laboratories) |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| GRAL-DEBT | Debt stack $51.0M | 90% | Market cache reports total debt of $51.0M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| GRAL-OWNER-MORGAN-STANLEY | MORGAN STANLEY | 90% | 13F overlay lists MORGAN STANLEY as top holder; 374 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| IVA | Inventiva S.A. | 100.00 | 2 | |
| GIFLF | Grifols, S.A. | 100.00 | 2 | |
| GH | Guardant Health, Inc. | 100.00 | 1 | ['receiving'] |
| ITGR | Integer Holdings Corporation | 100.00 | 2 | |
| RXRX | Recursion Pharmaceuticals, Inc. | 100.00 | 2 | |
| GCTK | GlucoTrack, Inc. | 100.00 | 2 | |
| GIKLY | Grifols, S.A. | 100.00 | 2 | |
| EXAS | Exact Sciences Corp | 100.00 | 1 | ['receiving'] |
| TEM | Tempus AI, Inc. | 100.00 | 1 | ['receiving'] |
| GIFOF | Grifols, S.A. | 100.00 | 2 | |
| PSNL | Personalis, Inc. | 100.00 | 2 | |
| ABT | Abbott Laboratories | 100.00 | 1 | ['customer'] |
| ACET | Adicet Bio, Inc. | 100.00 | 2 | |
| VTAK | Catheter Precision, Inc. | 100.00 | 2 | |
| SVA | Sinovac Biotech Ltd. | 100.00 | 2 | |
| GRFS | Grifols, S.A. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| FLGT | Fulgent Genetics, Inc. | 100.00 | 2 | |
| ALVO | Alvotech | 100.00 | 2 | |
| IBIO | iBio, Inc. | 100.00 | 2 |